FINERENONE

Information current as at: 1 September 2026

PBAC meeting date: November 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Kerendia®
Form and strength:
  • Tablet 10 mg
  • Tablet 20 mg
  • Tablet 40 mg
Submission sponsor:
BAYER AUSTRALIA LTD
Condition/indication:
(therapeutic use)
  • Heart failure
Listing requested:
To request listing of finerenone for the treatment of adult patients with symptomatic heart failure (New York Heart Association (NYHA) Class II-IV) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40%.
Funding program:
PBS General Schedule
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
November 2026 PBAC meeting
Opportunity for consumer comment:
Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC Outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:

Resubmission to request listing of finerenone for the treatment of adult patients with symptomatic heart failure (New York Heart Association (NYHA) Class II-IV) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40%.

Case ID
1260
Page last updated
04 September 2026
Return to the Medicine Status Listing
v.9.19